Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Markets & Finance

Pacific Growth Ups Pharmacyclics to Buy


From Standard & Poor's Equity Research

Pacific Growth upgraded Pharmacyclics (PCYC) to buy from neutral, noting that the company presented new analyses

Analyst George Wade says Dr. Minesh Mehta (Univ. Wisconsin Medical School) presented new analyses of a completed SMART trial on the company's Xcytrin Injection at a 2006 annual meeting of the American Society of Clinical Oncology. He says new analyses of the SMART trial on time to neurologic progression yields statistical significance. He also notes that the company's upgrade precedes anticipated catalysts within the coming 12 months, including the new drug application filing and its potential acceptance, among other things.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus